CytoDyn Inc (OTCMKTS:CYDY) CEO Nader Pourhassan tells Proactive it has filed for Breakthrough Therapy designation with the FDA for the use of its lead drug leronlimab as an adjuvant therapy for the treatment of metastatic triple-negative breast cancer (mTNBC). What's more, Pourhassan commented on recent interaction with potential investors from the Biotech Showcase 2020 in San Francisco.
CytoDyn files for breakthrough therapy status in metastatic triple-negative breast cancer
